On the other hand, MAPK pathway mutations (including BRAF and PTPN11) in GBM are associated with an improved response to PD-1 blockade, defined in one study as either stable or shrinking GBM volume on imaging or a minimal amount of tumor cells in tissue samples [126]. This evidence concerns the gene RPL17 and glioblastoma.